Phenylephrine

證據等級: L5

預測適應症: 3 個

Phenylephrine: From Nasal Decongestant to Nasal Cavity Disease

One-Sentence Summary

Phenylephrine is a selective α1-adrenergic receptor agonist most widely used clinically as a topical nasal/ocular decongestant and as a vasopressor. The TxGNN model predicts it may be formally effective for Nasal Cavity Disease, with 8 clinical trials and 8 publications currently supporting this direction — though the evidence largely documents phenylephrine's already established decongestant use rather than a novel therapeutic hypothesis.

Quick Overview

Item	Content
Original Indication	Not available in Norway regulatory data (no marketed license); pharmacologically established as a nasal/ocular decongestant and vasopressor
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.97%
Evidence Level	L2
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, DrugBank's formal mechanism-of-action field for phenylephrine is a data gap in this evidence pack. Based on well-established pharmacology captured in the repurposing rationale, phenylephrine is a selective α1-adrenergic receptor agonist that acts on vascular smooth muscle in the nasal mucosa, producing vasoconstriction that reduces mucosal congestion and edema — the classical decongestant mechanism.

This is not so much a novel repurposing hypothesis as a consolidation of already-documented clinical use: phenylephrine (alone or in combinations such as Cophenylcaine, Kovanaze, and Polydexa) is routinely used before nasoendoscopy, sinus surgery, and other nasal/ENT procedures to shrink mucosa and improve visualization and comfort. The predicted indication "Nasal Cavity Disease" therefore aligns tightly with existing off-label/adjunct practice rather than requiring mechanistic extrapolation.

This is why the evidence level here (L2) is meaningfully stronger than the other two candidate indications identified for this drug in the same evidence pack — acute laryngopharyngitis (L5, no trials/literature) and trigeminal autonomic cephalalgia (L4, phenylephrine used only as a diagnostic pupillometry reagent, not a treatment). For nasal cavity disease, the mechanism is direct, well-precedented, and supported by an actual Phase 2 RCT.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00562120	Phase 2	Completed	21	Double-blind, 4-way crossover RCT testing an H3-antagonist vs. nasal decongestant therapy on allergen-induced nasal congestion; most direct comparative evidence for this indication (Grade A)
NCT03380715	N/A	Completed	106	Co-phenylcaine (contains phenylephrine) nasal spray vs. nebulization for mucosal decongestion/anesthesia before rigid nasoendoscopy
NCT04104789	Phase 2	Withdrawn	0	Kovanaze (phenylephrine/tetracaine) nasal mist vs. articaine injection for maxillary pulpal anesthesia; trial withdrawn, no data generated
NCT03962634	Phase 2	Terminated	3	Same Kovanaze vs. articaine comparison; terminated early with negligible enrollment
NCT03228914	Phase 4	Completed	20	Compares oxymetazoline vs. epinephrine (not phenylephrine) for preoperative sinus surgery decongestion; indirect α-agonist class reference only
NCT02993770	N/A	Unknown	120	Endoscopic vs. external dacryocystorhinostomy surgical technique comparison; not a direct phenylephrine intervention trial
NCT06457100	Phase 1/2	Active, not recruiting	60	Esmolol vs. lidocaine infusion for recovery quality after functional endoscopic sinus surgery; phenylephrine not the studied agent
NCT06443255	Phase 3	Completed	16	Compares cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia during awake nasotracheal intubation; phenylephrine arm not included

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15854186	2005	RCT	Int J Clin Pract	Double-blind RCT of cophenylcaine spray (phenylephrine-containing) vs. placebo before flexible nasendoscopy; minimal pain/discomfort in both arms
40899890	2025	RCT/experimental	Vestnik otorinolaringologii	Safety/efficacy evaluation of Polydexa nasal spray with phenylephrine in acute rhinosinusitis
25133491	2014	RCT	PLoS One	Triple-blind RCT on topical tranexamic acid for bleeding/surgical field quality during FESS in chronic rhinosinusitis (adjunct nasal-cavity surgery context)
37184554	2023	Review	Vestnik otorinolaringologii	Endoscopic mucosal assessment after topical antibiotic therapy including Polydexa with phenylephrine for granulomatosis with polyangiitis
37970776	2023	Review	Vestnik otorinolaringologii	Pathogenesis-based treatment approach for inflammatory diseases of nose and paranasal sinuses
9780066	1998	Cohort	Int J Pediatr Otorhinolaryngol	Acoustic rhinometry of nasal cavity/nasopharynx geometry after adenotonsillectomy
7378007	1980	Case report	Arch Ophthalmol	Cocaine and intranasal phenylephrine toxicity during dacryocystorhinostomy; highlights sympathomimetic interaction risk
1375136	1992	In vitro / mechanism	Clin Otolaryngol Allied Sci	Dose-dependent effects of nasal drugs, including phenylephrine, on ciliary beat frequency in vitro

Norway Market Information

No marketed authorizations were found for phenylephrine in Norway under this evidence pack (total_licenses = 0). The drug is currently classified as 未上市 / Not marketed, so no product-level license table is available.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack — notably flagged as a Blocking gap (DG001: TFDA label warnings/contraindications) that prevents completion of the S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic basis is strong and non-novel — phenylephrine's decongestant effect on nasal mucosa is pharmacologically well-established and already reflected in real-world adjunct use (Cophenylcaine, Kovanaze, Polydexa) — and one Phase 2 crossover RCT (NCT00562120) provides direct comparative evidence, supporting an L2 evidence level. However, the drug is not currently marketed in this jurisdiction and a blocking safety data gap (TFDA/label warnings and contraindications) remains unresolved, so full clinical adoption cannot proceed without further data.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain and parse the official product label for warnings/contraindications before any S1 safety assessment
Resolve DG002 (High): confirm formal DrugBank/regulatory MOA documentation
Clarify route/dosage-form compatibility for the "nasal cavity disease" indication (intranasal spray vs. combination formulations)
Assess regulatory pathway feasibility given the drug currently has zero marketed licenses in this jurisdiction

Note on other predicted indications: Two additional candidates for phenylephrine were assessed in this evidence pack — acute laryngopharyngitis (L5, no supporting trials or literature, Hold) and trigeminal autonomic cephalalgia (L4, phenylephrine used only as a diagnostic pupillometry reagent for cluster headache/Horner's differentiation, not as treatment, Hold). Neither is recommended for further action at this time.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.